These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 3929681)

  • 1. In vitro activity of BMY-28142 against pediatric pathogens, including isolates from cystic fibrosis sputum.
    Conrad DA; Scribner RK; Weber AH; Marks MI
    Antimicrob Agents Chemother; 1985 Jul; 28(1):58-63. PubMed ID: 3929681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of BMY 28100, a new oral cephalosporin.
    Steele J; Edwards B; Rissing J
    Eur J Clin Microbiol; 1987 Feb; 6(1):111-3. PubMed ID: 3494601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of tosufloxacin, a new quinolone, against respiratory pathogens derived from cystic fibrosis sputum.
    Arguedas AG; Akaniro JC; Stutman HR; Marks MI
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2223-7. PubMed ID: 2073112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin.
    Neu HC; Chin NX; Jules K; Labthavikul P
    J Antimicrob Chemother; 1986 Apr; 17(4):441-52. PubMed ID: 3486862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro antibacterial activity of BMY-28142, a new extended-spectrum cephalosporin.
    Vuye A; Pijck J
    Antimicrob Agents Chemother; 1985 Apr; 27(4):574-7. PubMed ID: 3859244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative activity of cefepime, alone and in combination, against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients.
    Bosso JA; Saxon BA; Matsen JM
    Antimicrob Agents Chemother; 1991 Apr; 35(4):783-4. PubMed ID: 1906264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro activity of BMY 28142, a new aminothiazolyl cephalosporin.
    Steele JC; Edwards BH; Rissing JP
    J Antimicrob Chemother; 1985 Oct; 16(4):463-8. PubMed ID: 3840799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis.
    Gramegna A; Millar BC; Blasi F; Elborn JS; Downey DG; Moore JE
    J Glob Antimicrob Resist; 2018 Sep; 14():224-227. PubMed ID: 29559421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of E-1040, a 3-substituted cephalosporin, against pathogens from cystic fibrosis sputum.
    Stutman HR; Akaniro JC; Vidaurre CE; Marks MI
    Antimicrob Agents Chemother; 1990 Jul; 34(7):1366-70. PubMed ID: 2386368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1994)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Matsuda M; Tanimoto H; Nakata K; Nakamori Y; Kusano N
    Jpn J Antibiot; 1996 May; 49(5):419-55. PubMed ID: 8752860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents.
    Tsuji A; Maniatis A; Bertram MA; Young LS
    Antimicrob Agents Chemother; 1985 Apr; 27(4):515-9. PubMed ID: 3839120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity and beta-lactamase stability of the oral cephalosporin BMY-28100.
    Hiraoka M; Masuyoshi S; Tomatsu K; Inoue M; Mitsuhashi S
    Eur J Clin Microbiol; 1987 Oct; 6(5):559-63. PubMed ID: 3501756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of cefprozil (BMY 28100) and cefepime (BMY 28142) against Streptococcus pneumoniae, Branhamella catarrhalis, and Haemophilus influenzae, and provisional interpretive criteria for disk diffusion and dilution susceptibility tests with Haemophilus influenzae.
    Doern GV; Vautour R
    Diagn Microbiol Infect Dis; 1992; 15(7):633-40. PubMed ID: 1424521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vitro activity of cefepime (BMY 28142) against multiresistant nosocomial isolates of Pseudomonas aeruginosa.
    Voutsinas D; Mavroudis T; Avlamis A; Giamarellou H
    Eur J Clin Microbiol Infect Dis; 1989 Oct; 8(10):917-9. PubMed ID: 2512141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics.
    Kessler RE; Bies M; Buck RE; Chisholm DR; Pursiano TA; Tsai YH; Misiek M; Price KE; Leitner F
    Antimicrob Agents Chemother; 1985 Feb; 27(2):207-16. PubMed ID: 3885849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative antibacterial activity of the new oral cephalosporin BMY-28100.
    Kayser FH
    Eur J Clin Microbiol; 1987 Jun; 6(3):309-12. PubMed ID: 3497804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014.
    Pfaller MA; Mendes RE; Castanheira M; Flamm RK; Jones RN; Sader HS
    Pediatr Infect Dis J; 2017 May; 36(5):486-491. PubMed ID: 28403050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2005)].
    Goto H; Takeda H; Kawai S; Watanabe S; Okazaki M; Shimada K; Nakano K; Yokouchi H; Mori T; Igari J; Oguri T; Yamamoto M; Kudo K; Kobayashi N; Tanaka T; Yoshimura K; Kawabata M; Nakamori Y; Sumitomo M; Inoue H; Nakadate T; Suwabe A; Ashino Y; Aoki N; Honma Y; Suzuki Y; Karasawa Y; Oka M; Kobashi Y; Kohno S; Hirakata Y; Kondou A; Matsuda J; Nakano M; Oikawa S
    Jpn J Antibiot; 2008 Aug; 61(4):209-40. PubMed ID: 19024644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of BMY-28100, a new oral cephalosporin.
    Norden CW; Niederriter K
    Chemotherapy; 1988; 34(1):27-9. PubMed ID: 3258231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.